Cargando…
PTEN-Dependent Stabilization of MTSS1 Inhibits Metastatic Phenotype in Pancreatic Ductal Adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) presents at metastatic stage in over 50% of patients. With a survival rate of just 2.7% for patients presenting with distant disease, it is imperative to uncover novel mechanisms capable of suppressing metastasis in PDAC. Previously, we reported that the loss...
Autores principales: | Zeleniak, Ann E., Huang, Wei, Fishel, Melissa L., Hill, Reginald |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5714254/ https://www.ncbi.nlm.nih.gov/pubmed/29175021 http://dx.doi.org/10.1016/j.neo.2017.10.004 |
Ejemplares similares
-
Loss of MTSS1 results in increased metastatic potential in pancreatic cancer
por: Zeleniak, Ann E, et al.
Publicado: (2017) -
CANCER-ASSOCIATED FIBROBLAST EXOSOMES REGULATE SURVIVAL AND PROLIFERATION OF PANCREATIC CANCER CELLS
por: Richards, Katherine E., et al.
Publicado: (2016) -
MTA2-mediated inhibition of PTEN leads to pancreatic ductal adenocarcinoma carcinogenicity
por: Si, Wenzhe, et al.
Publicado: (2019) -
Exploring the Tumor-Suppressing Potential of PSCA in Pancreatic Ductal Adenocarcinoma
por: Li, Kexin, et al.
Publicado: (2023) -
Anticancer Peptides Derived from Aldolase A and Induced Tumor-Suppressing Cells Inhibit Pancreatic Ductal Adenocarcinoma Cells
por: Cui, Changpeng, et al.
Publicado: (2023)